Charles Schwab Investment Management Inc. Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Charles Schwab Investment Management Inc. grew its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 5.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 535,501 shares of the company’s stock after purchasing an additional 28,053 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.53% of Day One Biopharmaceuticals worth $6,785,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. FMR LLC grew its holdings in shares of Day One Biopharmaceuticals by 178.5% in the 3rd quarter. FMR LLC now owns 7,412,380 shares of the company’s stock worth $103,254,000 after acquiring an additional 4,750,936 shares during the period. Braidwell LP grew its holdings in Day One Biopharmaceuticals by 60.5% in the third quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock valued at $67,893,000 after purchasing an additional 1,837,949 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Day One Biopharmaceuticals by 2.3% in the third quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company’s stock valued at $55,336,000 after buying an additional 87,262 shares in the last quarter. Vestal Point Capital LP raised its stake in shares of Day One Biopharmaceuticals by 100.0% during the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $34,825,000 after buying an additional 1,250,000 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Day One Biopharmaceuticals by 18.4% in the 3rd quarter. Janus Henderson Group PLC now owns 2,177,197 shares of the company’s stock worth $30,307,000 after buying an additional 337,928 shares in the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. This trade represents a 10.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at $1,531,059.40. This represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock worth $251,925 in the last 90 days. 8.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have weighed in on DAWN. The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a report on Monday, February 10th. Wedbush reissued an “outperform” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. HC Wainwright reduced their target price on Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Bank of America lowered their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. cut their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Day One Biopharmaceuticals presently has an average rating of “Buy” and a consensus target price of $34.57.

Day One Biopharmaceuticals Stock Performance

DAWN stock opened at $8.31 on Tuesday. The company has a 50 day moving average price of $10.90 and a two-hundred day moving average price of $12.76. The stock has a market capitalization of $842.26 million, a P/E ratio of -8.07 and a beta of -1.38. Day One Biopharmaceuticals, Inc. has a one year low of $7.88 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to analyst estimates of $27.11 million. Research analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.